PLUS1
44.99
1.71 (3.95%)
1.71 (3.95%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| REGENXBIO Inc | RGNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 1.71 | 3.95% | 44.99 | 17:15:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 43.17 | 42.22 | 45.10 | 44.99 | 43.28 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 42.10 | 46.50 | 4.40 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,832 | 312,542 | $ 43.94 | $ 13,733,374 | 640,643 | 20.03 - 54.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:43:42 | priorref | 297 | $ 44.99 | USD |
REGENXBIO Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.90B | 42.31M | 28.51M | $ 35.23M | $ -17.20M | -2.59 | -17.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
REGENXBIO News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/12/2021 | 16:05 | PR Newswire (US) | REGENXBIO Announces Closing Of Public Offering Of Common.. |
| 1/11/2021 | 16:29 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/11/2021 | 07:05 | PR Newswire (US) | REGENXBIO to Present at the 39th Annual J.P. Morgan.. |
| 1/08/2021 | 16:26 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/08/2021 | 07:05 | PR Newswire (US) | REGENXBIO Announces Pricing Of Public Offering Of Common.. |
| 1/06/2021 | 16:35 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 1/06/2021 | 16:01 | PR Newswire (US) | REGENXBIO Announces Proposed Public Offering Of Common Stock |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGNX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 48.34 | 49.63 | 41.50 | 44.38 | 657,437 | -3.35 | -6.93% |
| 1 Month | 49.94 | 50.26 | 41.50 | 47.02 | 696,485 | -4.95 | -9.91% |
| 3 Months | 28.97 | 50.26 | 27.145 | 41.95 | 496,559 | 16.02 | 55.3% |
| 6 Months | 36.79 | 50.26 | 25.925 | 36.28 | 407,169 | 8.20 | 22.29% |
| 1 Year | 42.90 | 54.97 | 20.03 | 36.92 | 420,469 | 2.09 | 4.87% |
| 3 Years | 29.15 | 85.10 | 20.03 | 46.26 | 490,860 | 15.84 | 54.34% |
| 5 Years | 13.41 | 85.10 | 7.0701 | 40.38 | 385,981 | 31.58 | 235.5% |
REGENXBIO Description
| Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). |
